Get started
Author

Siddharth Kunte

Observed names: Kunte Siddharth, S. Kunte, SIDDHARTH KUNTE, Siddharth Jayant Kunte
ORCID: 0000-0002-5544-3410
Observed ORCID: 0000-0002-5544-3410
OpenAlex ID: A5058891069
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer
2020 · Siddharth Kunte, Jame Abraham, et al. · Cancer · 214
PDF
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes
2021 · Anna M Varghese, Isha Singh, et al. · JNCI Journal of the National Cancer Institute · 64
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
2021 · Siddharth Kunte, Lisa Rybicki, et al. · Leukemia · 43
PDF
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023 · Isao Miyazaki, Igor Odintsov, et al. · Nature Cancer · 42
PDF
Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score
2016 · Veronica Mariotti, David B. Page, et al. · Journal of bone oncology · 36
PDF
Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling
2021 · Roger S. Smith, Igor Odintsov, et al. · Disease Models & Mechanisms · 32
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
2023 · Mohammadhadi Khorrami, Vidya Sakar Viswanathan, et al. · npj Breast Cancer · 14
PDF
RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
2020 · Takuo Hayashi, Igor Odintsov, et al. · Disease Models & Mechanisms · 13
Poorly Differentiated Thyroid Carcinoma: Single Institution Series of Outcomes
2022 · SIDDHARTH KUNTE, JONATHAN SHARETT, et al. · Anticancer Research · 12
PDF
A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib
2020 · Siddharth Kunte, James Stevenson · Clinical Lung Cancer · 9
Demographic disparities in trend of gynecological cancer in the United States
2023 · Sishir Doddi, Oscar Salichs, et al. · Journal of Cancer Research and Clinical Oncology · 8
PDF
Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?
2017 · Fernando C. Santini, Siddharth Kunte, et al. · Translational Lung Cancer Research · 6
PDF
Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations
2021 · Igor Odintsov, Renate I. Kurth, et al. · Molecular Cancer Therapeutics · 5
Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience
2020 · Siddharth Jayant Kunte, Lisa Rybicki, et al. · Blood · 5
Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach
2020 · Roger S. Smith, Igor Odintsov, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4
PDF
Demographic Disparities in Acute Myeloid Leukemia Mortality Trends in the United States
2024 · SISHIR DODDI, OSCAR SALICHS, et al. · Anticancer Research · 3
Abstract P5-13-27: Post-treatment vascularity and vessel shape are associated with survival and response to CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer (MBC)
2022 · Vidya Sankar Viswanathan, Nathaniel Braman, et al. · Cancer Research · 3
Resazurin microtitre assay (REMA) plate - A simple, rapid and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis
2012 · Siddharth Kunte, Alaka Karmarkar, et al. · European Respiratory Journal · 3
Radiomics risk score (RRS) on CT to predict survival and response to CDK 4/6 inhibitors in hormone receptor (HR) positive metastatic breast cancer (MBC).
2020 · Siddharth Kunte, Nathaniel Braman, et al. · Journal of Clinical Oncology · 2
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023 · Isao Miyazaki, Igor Odintsov, et al. · Nature Cancer · 1
PDF
MA13.05 TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions
2022 · I. Odintsov, A.J.W. Lui, et al. · Journal of Thoracic Oncology · 1
PDF
Abstract PS5-42: Change in intra-lesion heterogeneity on CT predicts long-term survival following treatment with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer (MBC)
2021 · Nathaniel Braman, Siddharth Kunte, et al. · Cancer Research
Her2陽性転移性乳癌に対する新規her2標的治療【jst・京大機械翻訳】
2020 · Kunte Siddharth, Abraham Jame, et al. · Cancer (Hoboken, N.J.)
Survival outcomes among young small cell lung cancer (SCLC) patients and insurance status: A SEER analysis 2007-2014.
2018 · Qian Wang, Yaning Zhang, et al. · Journal of Clinical Oncology
Insurance disparity and outcomes among younger non-small cell lung cancer (NSCLC) patients: A SEER analysis 2007-2014.
2018 · Qian Wang, Changchuan Jiang, et al. · Journal of Clinical Oncology
Works count: 27
Citation count: 520
H-index: 9
I10-index: 9
Year
Topic
Type